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creativecommons.org/licenses/by-nc-nd/Abstract Purpose: Long-term trends in neuroblastoma incidence and survival in unscreened
populations are unknown. We explored trends in incidence, stage at diagnosis, treatment and
survival of neuroblastoma in the Netherlands from 1990 to 2014.
Methods: The Netherlands Cancer Registry provided data on all patients aged <18 years diag-
nosed with a neuroblastoma. Trends in incidence and stage were evaluated by calculating the
average annual percentage change (AAPC). Univariate and multivariable survival analyses
were performed for stage 4 disease to test whether changes in treatment are associated with
survival.
Results: Of the 593 newly diagnosed neuroblastoma cases, 45% was <18 months of age at
diagnosis and 52% had stage 4 disease. The age-standardized incidence rate for stage 4 disease
increased at all ages from 3.2 to 5.3 per million children per year (AAPC þ 2.9%, p < .01).ima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
acentrum.nl (M.L. Tas).
Equal contribution last author.
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
M.L. Tas et al. / European Journal of Cancer 124 (2020) 47e5548This increase was solely for patients 18 months old (3.0e5.4; AAPC þ3.3%, pZ .01). Five-
year OS of all patients increased from 44  5% to 61  4% from 1990 to 2014 (p < .01) and
from 19  6% to 44  6% (p < .01) for patients with stage 4 disease. Multivariable analysis
revealed that high-dose chemotherapy followed by autologous stem cell rescue and anti-GD2-
based immunotherapy were associated with this survival increase (HR 0.46, p < .01 and HR
0.37, p < .01, respectively).
Conclusion: Incidence of stage 4 neuroblastoma increased exclusively in patients aged 18
months since 1990, whereas the incidence of other stages remained stable. The 5-year OS of
stage 4 patients improved, mostly due to the introduction of high-dose chemotherapy followed
by stem cell rescue and immunotherapy.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of neuroblastoma (NB) in developed
countries is 11e13 per million children aged <15 years
and varies from 65 per million in children <1 year to 1
per million in children of 10e14 years [1e3]. NB is a
heterogeneous tumour entity with a variable clinical
course. The long-term survival is good to excellent in
low-risk disease (5-year OS of >85% in International
Neuroblastoma Staging System (INSS) stage 1, 2, 4S [4],
or International Neuroblastoma Risk Group Staging
System stage L1, MS [5]), but poor in patients with high-
risk disease (5-year OS of <50% in stage 4/M in patients
18 months old at diagnosis, and/or with MYCN (v-
myc avian myelocytomatosis viral related oncogene,
neuroblastoma derived) amplification) [6]. Furthermore,
patients with a more differentiated histology (ganglio-
neuroblastoma [GNB]) fare a more favourable course of
disease than patients with undifferentiated histology
(NB) [7,8]. In the past decades, therapy for high-risk
patients has been modified in several ways to increase
survival. Induction chemotherapy was intensified, high-
dose chemotherapy followed by autologous stem cell
rescue and standard radiotherapy were introduced.
Most recently, anti-GD2 immunotherapy has been
added to the maintenance therapy; this monoclonal
antibody is given in combination with alternating GM-
CSF or IL-2 to stimulate the immune response [9e12].
Improvements in cancer outcome are often analysed
as improvements in survival, but cancer incidence ana-
lyses should also be used to monitor changes in outcome
by changes in the prevalence of (unknown) risk factors
[13]. While survival provides a measure of prognosis and
improvement in the treatment, trends in cancer mor-
tality are the result of trends in both incidence and
survival. The three analyses together increase the
comprehension of the total progress against cancer in a
given area over time [14e16].
These epidemiological analyses were used in the
evaluations of the NB screening programs, conducted
between 1985 and 2000 in Japan and parts of Germany,France, Austria, Canada and the United Kingdom. The
rationale behind the screening programs was that
detection at an earlier stage of disease would lead to an
improved prognosis. Although the screening studies
identified more young patients with low-risk NB, this
had no effect on incidence of high-risk disease or overall
mortality, suggesting overdiagnosis of low-risk patients
[13,16e22]. This resulted in the termination of all
screening programs. A disadvantage of these screening
programs is that change in the incidence over time. In
the Netherlands, no screening programs have been
performed.
The purpose of this comprehensive, population-based
study was to describe the trends in incidence, treatment
modalities and survival in NB patients aged <18 years,
diagnosed between 1990 and 2014, and to study the ef-
fect of changes in treatment on the survival of patients
with stage 4 NB.
2. Methods
2.1. Data sources
The Netherlands Cancer Registry (NCR) is a nation-
wide population-based registry, established in 1989,
hosted by the Netherlands Comprehensive Cancer Or-
ganization (IKNL). The NCR only registers persons
with the Dutch nationality, or people who have been
living in the Netherlands for at least three months before
diagnosis. Trained registrars of the NCR extracted data
on patient and tumour characteristics, and given treat-
ment by retrospective medical record review. Only first-
line treatment modalities were registered.
The NCR registers morphology according to the In-
ternational Classification of Diseased for Oncology
(ICD-O-3) [23], currently the ICD-O-3.1 system [24].
Tumour stage was recorded using the TNM classifica-
tion [25] until 2003 and subsequently according to the
Extent of Disease [26] (EoD) classification. Localized
disease (TNM/EoD) was converted to INSS stage 1/2,
regional disease to stage 3 and metastatic disease to
Table 1
Patient characteristics of patients aged <18 years, diagnosed with a neuroblastoma in the Netherlands between 1990 and 2014.
Characteristics 1990e1994 1995e1999 2000e2004 2005e2009 2010e2014 total
n (%) n (%) n (%) n (%) n (%) n (%)
Age
<18 months 45 (45) 54 (48) 56 (45) 57 (45) 53 (41) 265 (45)
18 months 55 (55) 59 (52) 68 (55) 69 (55) 77 (59) 328 (55)
Gender
Male 53 (53) 61 (54) 76 (61) 66 (52) 67 (52) 323 (54)
Female 47 (47) 52 (46) 48 (39) 60 (48) 63 (48) 270 (46)
Histology
NB 90 (90) 89 (79) 106 (85) 107 (85) 117 (90) 509 (86)
GNB 10 (10) 24 (21) 18 (15) 19 (15) 13 (10) 84 (14)
Stage
1/2 26 (27) 37 (33) 39 (32) 34 (27) 26 (20) 162 (28)
3 14 (15) 13 (12) 15 (12) 15 (12) 16 (12) 73 (12)
4 47 (49) 52 (46) 63 (52) 67 (54) 77 (59) 306 (52)
4S 9 (9) 10 (9) 5 (4) 9 (7) 11 (8) 44 (8)
Unknown 4 1 2 1 0 8
Localization primary tumour
Sympathetic side chain 23 (23) 32 (28) 32 (26) 33 (26) 37 (28) 157 (27)
- Cervical/thoracic 13 (13) 19 (17) 18 (15) 13 (10) 26 (20) 89 (15)
- Pelvic 5 (5) 7 (6) 6 (5) 8 (6) 4 (3) 30 (5)
- Not otherwise specifieda 5 (5) 6 (5) 8 (6) 12 (10) 7 (5) 38 (6)
Adrenal/abdominal 70 (70) 79 (70) 88 (71) 91 (72) 90 (69) 417 (70)
Unknown/no primary tumour 7 (7) 2 (2) 4 (3) 2 (2) 3 (2) 18 (3)
Abbreviations: NB, neuroblastoma; GNB, ganglioneuroblastoma.
Bold fonts indicate characteristics categories, italic fonts indicate subgroups.
a Sympathetic side chain tumours, without specified location.
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ities, hospital-based NB databases were used to cross-
check these items and to identify patients with NB
stage 4S, according to the INSS staging system [4]. In-
formation on risk stratification, MYCN status and
other genetic prognostic factors was not available.
2.2. Patient and data selection
Clinical data from Dutch patients aged <18 years at
diagnosis and diagnosed with a NB or a GNB between
1990 and 2014 were extracted from the NCR. Infor-
mation on vital status (alive, dead, or emigration) was
obtained by annual linkage with the Nationwide Popu-
lation Registries Network that contains vital statistics
on all Dutch residents. Last linkage was on February 1,
2018. Because of privacy regulations, no data on cause
of death could be obtained. Nationwide disease-specific
mortality data were not informative because NB was
non-consistently coded as a malignancy of the adrenal
gland, the connective and soft-tissues, and the peripheral
nervous system [27].
2.3. Statistical analyses
For the NB patient population, the following charac-
teristics were described: age at diagnosis, gender, his-
tology (NB vs. GNB), stage and location of the primary
tumour. Differences in these characteristics were testedusing c2 tests. For analysis over time, five-year periods
were defined: 1990e1994, 1995e1999, 2000e2004,
2005e2009 and 2010e2014.
Overall incidence rates were calculated as the average
annual number of cases per 1 million person-years, using
annual midyear population sizes from Statistics
Netherlands, these were provided for the age groups: 0,
1e4, 5e9, 10e14, and 15e17 years. Incidence rates were
also calculated for age groups (<18 and  18 months),
stage and stage per age group. The population at risk<18
monthswas calculated as the population aged 0 years plus
1/8th of the population aged 1e4 years. Similarly, the
population at risk 18 months was calculated as the
population aged 5e17 years plus 7/8th of the population
aged 1e4 years. Rates were age-standardized using the
age structure of the world standard population [28].
Changes in incidence over time were evaluated by calcu-
lating the average annual percentage change (AAPC).
AAPC was derived from a regression line fitted to the
natural logarithm of the rates, using the calendar year as
regressor variable (i.e. yZ axþ b where yZ ln (rate) and
x Z calendar year; then AAPC Z 100  (ea - 1)) and
calculated for the whole study period 1990e2014 [28].
Traditional cohort-based survival analysis using
KaplaneMeier method with log-rank test was used to
calculate overall survival (OS). Survival time was
calculated as the time elapsed between the date of
diagnosis and the date of death of any cause or date at
last follow-up (alive, censored).
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modalities were dichotomized to yes/no (see Table 2).
Differences in frequency of applied treatment modalities
by period of diagnosis were tested using c2 tests.
Time trends in observed 5-year OS were first evalu-
ated by using a parametric survival model. The dichot-
omized treatment modalities were added to the model to
investigate the effect of therapy on the hazard ratio
(HR) of period of diagnosis. Age group (<18 and  18
months), a strong independent predictor of survival, was
also entered in the multivariable models. All statistical
analyses were two-sided and a p-value <0.05 was
considered significant. Analyses were performed with
STATA/SE 14.2 (StataCorp LP, College Station, TX,
2015).3. Results
3.1. Patient characteristics
Between 1990 and 2014, 509 newly diagnosed patients
with NB and 84 with GNB were registered by the NCR,
of which 583 (98%) were histologically confirmed. Pa-
tient and tumour characteristics are presented in Table
1. Median age at diagnosis was 21 months (rangeFig. 1. Stage distribution of neuroblastoma patients aged <18
and ‡ 18 months at diagnosis. For patients <18 months and 18
months of age, the percentage (number of patients between pa-
rentheses) of each stage at diagnosis is given. Blue: stage 4S; red:
stage 4; orange: stage 3; green: stage 1/2. Two patients were
diagnosed as stage 4S, while they were 18 months of age. Stage
of disease was unknown in 8 patients, 7 of them aged <18 months
and were not included in this graph. Abbreviations: mo.: months;
st.: stage. (For interpretation of the references to colour in this
figure legend, the reader is referred to the Web version of this
article.)0e16 years), male sex was slightly predominant (54%;
male/female ratio Z 1.2:1). Seventy percent of the pa-
tients had an adrenal or abdominal primary tumour.
Most patients were diagnosed with stage 4 disease
(52%), followed by stage-1/2 disease (28%), stage 3
(12%), and stage 4S (8%). For 8 patients, no data were
available on stage of disease (Table 1). In patients aged
<18 months, stage 1/2 was the most common (41%), and
stage 4 disease was observed in 26% of the patients. In
patients aged 18 months, stage 4 dominated (73%;
Fig. 1).
3.2. Incidence
In the time period 1990e1994, on average, 20 new pa-
tients per year were diagnosed with NB; this increased to
26 patients per year between 2010 and 2014 (Fig. 2A).
The overall incidence rate (all stages, <18 years)
significantly increased by 1.6% per year from 6.4 to 9.1
per million between 1990 and 2014 (p Z .01; Fig. 2B).
Stage 4 NB increased with 2.9% per year (p < .01), while
the incidence of all other stages remained stable
(Fig. 2B). Incidence rates by age, gender, histological
type and stage, as well as the AAPC analyses for NB
patients aged <15 years are provided in Appendix Table
A1. No other significant changes in these rates were
observed.
The age-specific incidence rates for patients aged <18
and  18 months by stage are shown in Fig. 2C and D.
Incidence rates were stable for all stages in patients aged
<18 months, whereas an increase in incidence of stage 4
NB was seen in patients aged 18 months (AAPC
þ3.3%, p Z .01). For this age group, the number of
stage 4 patients almost doubled from 7 patients per year
in 1990e1994 to 12 patients per year in 2010e2014. The
incidence rates for the other stages in patients aged 18
months remained stable.
3.3. Therapy and survival
The 5-year survival rates varied by stage: 93  2% in
stage 1/2 disease; 84  6% in stage 4S; 70  5% in stage 3
disease; 35  3% in stage 4 disease (Fig. 3A). Five-year
OS of all patients improved from 44  5% in 1990e1994
to 61  4% in 2010e2014 (p < .01) (Fig. 3B). Five-year
OS of patients with stage 4 NB improved significantly
from 19  6% in 1990e1994 to 44  6% in 2010e2014
(p < .01; Fig. 4A). For patients with the poorest
outcome (stage 4 and  18 months old), 5-year OS
significantly improved from 6  4% in 1990e1994 to
43  7% in 2010e2014 (p < .01; Fig. 4B). The 5- and 10-
year OS rates over time for gender, age group, histologic
type and stage are summarized in Appendix Table A2.
Important changes in the treatment of patients with
stage 4 disease were made between 1990 and 2014. High-
dose chemotherapy with autologous stem cell
transplantation was given in 21% of patients with stage
’90-’94 ’95-’99 ’00-’04 ’05-’09 ’10-’14
0
25
50
75
100
125
150
Period
nu
m
be
ro
fp
at
ie
nt
s
st. 1/2
st. 3
st. 4
st. 4S
unknown
47
(49%)
9 (9%)
14 (15%)
4
26
(27%)
52
(46%)
13 (12%)
1
37
(33%)
10 (9%)
63
(52%)
15 (12%)
39
(32%)
5 (4%)
2 1
0
67
(54%)
15 (12%)
34
(27%)
9 (7%)
77
(59%)
16 (12%)
26
(20%)
11 (9%)
’90-’94 ’95-’99 ’00-’04 ’05-’09 ’10-’14
0.0
2.0
4.0
6.0
8.0
10.0
Period
In
ci
de
nc
e
ra
te
pe
r1
06
st. 1/2 (-0.5%, p=.80)
st. 3 (+1.4%, p=.28)
st. 4 (+2.9%, p<.01)
st. 4S (+3.9%, p=.41)
total (+1.6%, p=.01)
’90-’94 ’95-’99 ’00-’04 ’05-’09 ’10-’14
0.0
10.0
20.0
30.0
40.0
50.0
Period
In
ci
de
nc
e
ra
te
pe
r1
06
st. 1/2 (-2.0%, p=.73)
st. 3 (+7.3%, p=.06)
st. 4 (+1.9%, p=.24)
st. 4S (+5.2%, p=.51)
total (+1.8%, p=.08)
’90-’94 ’95-’99 ’00-’04 ’05-’09 ’10-’14
0.0
2.0
4.0
6.0
8.0
Period
In
ci
de
nc
e
ra
te
pe
r1
06
st. 1/2 (-2,7%, p=.53)
st. 3 (+0.6%, p=.90)
st. 4 (+3.3%, p=.01)
total (+1.6%, p=.10)
A
C
B
D
Fig. 2. Time trends in neuroblastoma incidence per five year period. The number of newly diagnosed patients (percentage in parentheses) is
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M.L. Tas et al. / European Journal of Cancer 124 (2020) 47e55 514 between 1990 and 1999 and in 69% between 2010 and
2014 (p < .01); the frequency of primary tumour surgery
increased from 58% to 84% (p < .01); radiotherapy
increased from 16% to 40% (p < .01); immunotherapy
increased from 0% in 1990e1999 to 4% in 2005e2009
and 53% in 2010e2014 (p < .01). The number of pa-
tients receiving 131I-MIBG-therapy (39%) and chemo-
therapy (98%) did not change between 1990 and 2014.3.4. Multivariable survival analysis for stage 4
neuroblastoma
In univariate analysis, the risk of dying (HR) from stage
4 NB was significantly lower during the periods
2005e2009 and 2010e2014 compared with 1990e1994
(HR 0.54, p Z .01 and HR 0.50, p < .01, respectively).
Patients aged 18 months had a poorer survival prob-
ability (HR 2.12, p < .01) than patients aged <18
months (Table 2). Other prognostic factors were the
treatment modalities high-dose chemotherapy with stem
cell rescue, immunotherapy and surgery. The first
multivariable model contained age and period of diag-
nosis. In this model, the two most recent periods of
diagnosis were associated with better outcome (HR 0.52and 0.44, pZ .01 and p < .01, respectively). Addition of
the different treatment modalities to a second multi-
variable model resulted in the loss of significance for the
HRs of these recent periods of diagnosis (HR 0.85 and
1.14, p Z .52 and p Z .60, respectively; Table 2). Pa-
tients who received high-dose chemotherapy with stem
cell rescue (HR 0.46, p < .01) and patients who received
immunotherapy (HR 0.37, p < .01) had a significant
reduction of the risk of dying. The changes in the
treatment modalities were better discriminants for the
changes in survival over time, than the periods of
diagnosis (Table 2).4. Discussion
This is the first report on incidence and survival of
children and adolescents with an NB in the Netherlands.
Over a 25-year period, we observed a significant increase
in incidence of stage 4 disease in patients aged 18
months, while the incidence of other stages and ages
remained stable. Five-year OS improved for all ages and
stages, the most distinct for patients aged 18 months
with stage 4 NB, where an improvement of 37 percent-
age points was seen.
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M.L. Tas et al. / European Journal of Cancer 124 (2020) 47e5552The age-standardized incidence rate of around 10.5
cases per million children in 2010e2014 observed in this
study is similar to other high-income countries as Can-
ada, USA, and neighbouring European countries (WSR
0e14 years 10.1e15.0) [29,30]. The overall increase in
NB incidence of 1.6% per year is in line with the increase
in NB incidence in older children (1e4 year) of 1.7% per
year in Europe (1978e1997), and of 1.6% per year in
Canada (1992e2010) [2,3]. However, in Denmark, NB
incidence has been stable between 1981 and 2000 for all
stages and age categories [31], whereas in England, a
slight decrease in incidence of 0.2% for all stages and age0 12 24 36 48 60
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Germany, analyses of both tumour stage and age were
performed. They found a small (7% per 10 year) increase
in overall incidence, but this was attributed to an in-
crease in stage 1e3 and stage 4S and a decrease in stage
4, which is contradicting our data [32]. Etiological fac-
tors for NB are largely unknown other than ‘it is a
developmental tumour of the sympathetic nervous sys-
tem’. Genetic predisposition is rare (estimated at 1e2%)
[33], and no environmental factors have been consis-
tently associated with NB [34]. Improved prenatal ul-
trasounds only contribute to an increase in patients aged0 12 24 36 48 60
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Table 2
Univariate and multivariable analyses for 5-year overall survival of patients with stage 4 neuroblastoma by age group, period of diagnosis and
treatment modalities.
n Univariate analysis Multivariable analysis,
model without treatment modalities
Multivariable analysis, model with
treatment modalities
HR 95% CI p HR 95% CI p HR 95% CI p
Age groups
<18 months 67 Ref. Ref. Ref.
18 months 239 2.16 1.44 e 3.25 <0.01 2.31 1.53 e 3.48 <0.01 3.21 2.10 e 4.91 <0.01
Period
1990e1994 47 Ref. Ref. Ref.
1995e1999 52 0.89 0.57 e 1.40 0.62 0.84 0.53 e 1.32 0.44 1.03 0.65 e 1.64 0.88
2000e2004 63 0.72 0.47 e 1.12 0.15 0.65 0.42 e 1.01 0.06 0.95 0.60 e 1.51 0.83
2005e2009 67 0.54 0.34 e 0.85 0.01 0.52 0.33 e 0.82 0.01 0.85 0.53 e 1.38 0.52
2010e2014 77 0.50 0.32 e 0.78 <0.01 0.44 0.28 e 0.69 <0.01 1.14 0.69 e 1.90 0.60
ASCT
No 151 Ref. Ref.
Yes 155 0.45 0.34 e 0.60 <0.01 0.46 0.32 e 0.64 <0.01
Surgery
No 82 Ref. Ref.
Yes 224 0.58 0.43 e 0.79 <0.01 0.75 0.54 e 1.04 0.09
Immunotherapy
No 262 Ref. Ref.
Yes 44 0.38 0.23 e 0.62 <0.01 0.37 0.19 e 0.72 <0.01
Radiotherapy
No 214 Ref. Ref.
Yes 92 0.76 0.55 e 1.03 0.08 1.21 0.84 e 1.74 0.30
HRs were corrected for follow-up time.
Abbreviations; ASCT, autologous stem cell transplantation after high-dose chemotherapy; HR, hazard ratio; 95% CI, 95% confidence interval.
Bold fonts indicate characteristics categories.
M.L. Tas et al. / European Journal of Cancer 124 (2020) 47e55 53<18 months at diagnosis. In fact, this has also been
shown in NB screening studies based on urinary cate-
cholamine measurements in infants [17,20,35]. Higher
registration rates caused by immigration for medical
reasons can be ruled out because the Netherlands has a
long-standing population-wide cancer registry, covering
at least 95% of all newly diagnosed malignancies in
Dutch inhabitants [36].
The increase in overall incidence is caused by an in-
crease in the incidence of stage 4 NB in patients aged
18 months. In this group, the number of newly diag-
nosed patients almost doubled. The increase cannot be
assigned to higher sensitivity of molecular markers
(amplification of MYCN or loss of heterozygosity of
chromosome 1p) because these influence risk stratifica-
tion and not stage of disease. Improved sensitivity of
diagnostics and upstaging of patients with lower stage
disease can play a small role, but seems to be
negligible because only a minimal (non-significant)
decrease in lower stage disease was observed, while there
was a significant increase in overall incidence and in
stage 4 incidence. This leaves the cause of the increased
incidence for this subgroup unclear.
The improved survival for patients with stage 4
disease is associated with changes in therapy. Multivari-
able analysis showed that high-dose chemotherapy fol-
lowed by autologous stem cell rescue and
immunotherapy (HR 0.46, p< .01 and HR 0.37, p< .01)
were the treatment modalities that more adequatelypredicted the survival improvement than the periods of
diagnosis. Berthold et al. and Pinto et al. [9,37] reported
previously of a survival benefit for high-dose chemo-
therapy in high-risk NB, compared with maintenance
therapy. Immunotherapy was introduced in 2009, and in
this cohort, only 44 of the 306 patients with stage 4 dis-
ease received immunotherapy. Despite this very small
number, we observed a significant effect on OS in both
the univariate (HR 0.38, p < .01) and multivariable
analysis (HR 0.37, p< .01). This cohort seems to confirm
earlier studies demonstrating a benefit for maintenance
therapy with immunotherapy [12,38]. In addition, we
expect roles for the intensified induction chemotherapy
and the improved supportive care over time, but the
current data set did not allow these analyses.
The longstanding population-based Netherlands
Cancer Registry follows international standards and
coding practices, and has, also through its participation
in international projects (Eurocare, ACCIS, CI 5), many
quality checks. The NCR is one of the few registries that
also register stage and initial treatment. A limitation of
this study is the lack of data on prognostic markers such
as MYCN amplification and on cause of death. How-
ever, because the pediatric population in this study is
not suspected for other serious underlying diseases or
competing causes of death, the observed survival, as
reported here, is representative for the NB-specific sur-
vival [39]. Another limitation is the relative small size of
the Dutch population, resulting in a smaller cohort than
M.L. Tas et al. / European Journal of Cancer 124 (2020) 47e5554the German, European, or American SEER databases
[1,32,39].
5. Conclusions
Our population-based study comprehensively analysed
incidence, incidence changes over time, survival, and
treatment of NB during a 25-year period in the
Netherlands. We observed an increase of 1.6% per year
in total incidence and more particularly for patients with
stage 4 disease who were 18 months of age. Survival
for this group improved from 6  4% in 1990e1994 to
43  7% in 2010e2014. The improved survival of stage 4
patients is predominantly associated with the introduc-
tion of high-dose chemotherapy with autologous stem
cell rescue and immunotherapy.
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